Pluristem Therapeutics (PSTI) Preliminary COVID-19 Results a 'Game Changer' - H.C. Wainwright
Tweet
Share
E-mail
Get Alerts PSTI Hot Sheet
Price: $1.00 --0%
Rating Summary:
7 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $15.50 price target on Pluristem Therapeutics (NASDAQ: PSTI) saying today's strong preliminary COVID-19 results are a "game-changer."
Pluristem announced that six of the seven patients have completed the seven day follow up period and the preliminary data demonstrated 100% survival rate as of today.
For an analyst ratings summary and ratings history on Pluristem Therapeutics click here. For more ratings news on Pluristem Therapeutics click here.
Shares of Pluristem Therapeutics closed at $3.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Street Research Upgrades Micron Technology (MU) to Buy
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Tesla Nears Unveiling of Radical New ‘Flying’ Roadster - The Information
Create E-mail Alert Related Categories
Analyst Comments, FDA, Hot Comments, Momentum Movers, Trader TalkRelated Entities
H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
